Rebecca Fitzgerald - Selected Publications#

From Google Scholar:

Citations 18053
h-index 72
i10-index 207

1. Nowicki-Osuch K, Zhuang J, Jammula S, Vleaney CW, Mahbubani KT, Devonshire G, Katz- Summercorn A, Eliing N, Wilbrey-Clark A, Madissoon E, Gamble J, Di Pietro M, O’Dononvan M, Meyer KB, Saeb-Parsey K. Sharrocks A, Teichmann SA, Marioni JC, Fitzgerald RC. Molecular phenotyping reveals the identity of Barrett’s esophagus and its malignant transition Science 373; 760-767 2021 doi: I:10.1126/SCIENCE.ABD1449

2. Gehrung M, Crispin-Ortuzar, Berman AG, O’Donovan M, Fitzgerald RC (corresponding) and Markowetz F (corresponding). Triage-driven diagnosis of Barrett’s esophagus for early detection of esophageal adenocarcinoma using deep learning. Nature Medicine 2021; 27:833-841

3. Killcoyne S, Gregson E, Wedge DC, Woodcock DJ, Eldridge MD, de la Rue R, Miremadi A, Abbas S, Blasko A, Kosmidou C, Januszewicz W, Jenkins AV, Gerstung M, Fitzgerald RC. Genomic copy number predicts esophageal cancer years before transformation. Nat Med. 2020 Sep 7. doi: 10.1038/s41591-020-1033-y. PMID: 32895572

4. Fitzgerald RC, di Pietro M, O’Donovan M, Maroni R, Muldrew B, Debiram-Beecham I, Gehrung M, Offman J, Tripathi M, Smith SG, Aigret B, Walter FM, Rubin G, on behalf of the BEST3 Trial team, Sasieni P. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a prospective, multicentre, pragmatic, randomised controlled trial. The Lancet 2020 Aug;396(10247):333-344. doi: 10.1016/S0140-6736(20)31099-0.

5. Noorani A, Li X, Goddard M, Crawte J, Alexandrov LB, Secrier M, Eldridge MD, Bower L, Weaver J, Lao-Sirieix P, Martincorena I, Debiram-Beecham I, Grehan N, MacRae S, Malhotra S, Miremadi A, Thomas T, Galbraith S, Petersen L, Preston SD, Gilligan D, Hindmarsh A, Hardwick RH, Stratton MR, Wedge DC, Fitzgerald RC. Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nature Genetics, 2020; 52(1):74-83.

6. Perner J, Abbas S, Nowicki-Osuch K, Devonshire G, Eldridge MD, Tavaré S, Fitzgerald RC. The mutREAD method detects mutational signatures from low quantities of cancer DNA. Nature Communications 2020; 11(1):3166.

7. Frankell AM, Jammula S, Contino G, Killcoyne S, Abbas S, Perner J , Bower L , Devonshire G, Grehan N, Mok J, O’Donovan M, MacRae S , Tavare S, Fitzgerald RC and the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. The landscape of selection in 551 Esophageal Adenocarcinomas defines genomic biomarkers for the clinic. Nature Genetics 2019; 51(3):506-516.

8. Li X, Kleeman S, Coburn SB, Fumagalli C, Perner J, Jammula S, Pfeiffer RM, Orzolek L, Hao H, Taylor PR, Miremadi A, Galeano-Dalmau N, Lao-Sirieix P, Tennyson M, MacRae S, Cook MB, Fitzgerald RC. Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus. Gastroenterology 2018; 155(3):771-783.

9. Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, BEST2 study-site authors, and Fitzgerald RC. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. The Lancet Gastroenterology and Hepatology. 2017; 2(1), 23-31.

10. Secrier M, Li X, de Silva N, Eldridge MD, Contino G, Bornschein J, MacRae S, Grehan N, O'Donovan M, Miremadi A, Yang TP, Bower L, Chettouh H, Crawte J, Galeano-Dalmau N, Grabowska A, Saunders J, Underwood T, Waddell N, Barbour AP, Nutzinger B, Achilleos A, Edwards PA, Lynch AG, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nature Genetics 2016; 48(10):1131-41.